Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for JANX
| Stock Name | Janux Therapeutics Inc |
| Ticker | JANX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US47103J1051 |
Show aggregate JANX holdings
News associated with JANX
- Stifel Nicolaus Reiterates Buy Rating for Janux Therapeutics (NASDAQ:JANX)
- Stifel Nicolaus restated their buy rating on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research report report published on Wednesday, Marketbeat Ratings reports. Stifel Nicolaus currently has a $45.00 price target on the stock. Other research analysts have also recently issued research reports about the company. Piper Sandler assumed coverage on Janux […] - 2025-09-11 04:40:25
- The Math Shows SCHA Can Go To $31
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 09:07:38
- Y Intercept Hong Kong Ltd Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
- Y Intercept Hong Kong Ltd acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 17,833 shares of the company’s stock, valued at approximately $481,000. Other hedge funds and other institutional […] - 2025-07-28 06:14:50
- Janux Therapeutics (NASDAQ:JANX) Research Coverage Started at Raymond James Financial
- Raymond James Financial started coverage on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a report released on Friday, MarketBeat.com reports. The brokerage issued an outperform rating and a $65.00 price target on the stock. Janux Therapeutics Price Performance Janux Therapeutics stock opened at $25.15 on Friday. The firm has a market capitalization of […] - 2025-07-14 03:46:45
- KBC Group NV Makes New $66,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)
- KBC Group NV acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,461 shares of the company’s stock, valued at approximately $66,000. Other hedge funds and […] - 2025-07-09 04:33:52
- Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages
- Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have been assigned an average rating of “Buy” from the eleven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to […] - 2025-06-26 04:34:55
- Exchange Traded Concepts LLC Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
- Exchange Traded Concepts LLC increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 20.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,043 shares of the company’s stock after buying an additional 686 shares during the period. Exchange Traded […] - 2025-06-25 04:56:58
- SG Americas Securities LLC Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
- SG Americas Securities LLC purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the first quarter, Holdings Channel reports. The fund purchased 28,631 shares of the company’s stock, valued at approximately $773,000. Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group […] - 2025-06-20 05:12:52
- Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 532.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,737 shares of the company’s […] - 2025-06-01 05:33:05
- Two Sigma Investments LP Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
- Two Sigma Investments LP lessened its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 22.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,974 shares of the company’s stock after selling 17,218 shares during the […] - 2025-05-30 04:50:55
- Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Squarepoint Ops LLC
- Squarepoint Ops LLC grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 155.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,176 shares of the company’s stock after purchasing an additional 25,034 shares during the period. […] - 2025-05-29 05:18:55
- ProShare Advisors LLC Purchases 2,003 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
- ProShare Advisors LLC increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 23.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,384 shares of the company’s stock after acquiring an additional 2,003 shares during the quarter. ProShare […] - 2025-05-26 05:19:11
- Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts
- Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has earned an average recommendation of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the […] - 2025-05-20 02:39:02
- Deutsche Bank AG Has $4.98 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
- Deutsche Bank AG raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 386.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,029 shares of the company’s stock after acquiring an additional 73,912 shares during the quarter. Deutsche Bank AG’s […] - 2025-05-19 04:55:22
- Northern Trust Corp Purchases 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
- Northern Trust Corp boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 15.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 308,800 shares of the company’s stock after acquiring an additional 42,302 shares during the quarter. Northern Trust Corp’s holdings in Janux Therapeutics were worth $16,533,000 as of its most […] - 2025-05-15 04:54:52
- Janux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider Selling
- Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) shares gapped down prior to trading on Monday after an insider sold shares in the company. The stock had previously closed at $32.88, but opened at $30.00. Janux Therapeutics shares last traded at $30.73, with a volume of 453,943 shares changing hands. Specifically, insider Andrew Hollman Meyer […] - 2025-05-07 02:20:58
- Tower Research Capital LLC TRC Purchases 3,436 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
- Tower Research Capital LLC TRC boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 878.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,827 shares of the company’s stock after purchasing an additional 3,436 shares during the period. Tower Research Capital LLC TRC’s […] - 2025-05-06 05:08:51
- 128,062 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by First Trust Advisors LP
- First Trust Advisors LP purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 128,062 shares of the company’s stock, valued at approximately $6,856,000. Several other hedge funds have also made changes to their positions in JANX. […] - 2025-04-30 05:52:59
- Marshall Wace LLP Sells 25,703 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
- Marshall Wace LLP trimmed its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 53.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,348 shares of the company’s stock after selling 25,703 shares during the quarter. Marshall Wace LLP’s holdings […] - 2025-04-30 05:04:57
- Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $95.25
- Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has been given an average recommendation of “Buy” by the eleven analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the […] - 2025-04-28 02:39:12
- Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Barclays PLC
- Barclays PLC boosted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 51.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 263,970 shares of the company’s stock after purchasing an additional 89,909 shares during the period. […] - 2025-04-21 05:38:44
- Orion Portfolio Solutions LLC Has $263,000 Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)
- Orion Portfolio Solutions LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 25.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,913 shares of the company’s stock after selling 1,692 shares during the quarter. Orion Portfolio Solutions LLC’s […] - 2025-04-10 05:45:05
- 9,378 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Purchased by Sei Investments Co.
- Sei Investments Co. acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,378 shares of the company’s stock, valued at approximately $502,000. Several other large investors also recently added to or […] - 2025-04-10 04:18:49
- Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Franklin Resources Inc.
- Franklin Resources Inc. grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 2,519.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 497,287 shares of the company’s stock after purchasing an additional 478,304 shares during the quarter. Franklin Resources Inc. […] - 2025-04-07 06:11:08
- Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Corebridge Financial Inc.
- Corebridge Financial Inc. trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 7.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,940 shares of the company’s stock after selling 1,053 shares during the period. Corebridge […] - 2025-04-07 04:32:49
- Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $92.44 Consensus Target Price from Analysts
- Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have been given a consensus rating of “Buy” by the twelve analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on […] - 2025-04-03 02:36:47
- Bank of New York Mellon Corp Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
- Bank of New York Mellon Corp trimmed its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 9.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 78,859 shares of the company’s stock after selling 7,976 shares during the quarter. Bank of New York Mellon Corp’s holdings in Janux Therapeutics were worth […] - 2025-03-19 05:08:43
- Victory Capital Management Inc. Boosts Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)
- Victory Capital Management Inc. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 715.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 242,409 shares of the company’s stock after buying an additional 212,664 shares during the quarter. Victory Capital Management […] - 2025-03-13 06:32:52
- Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month Low After Analyst Downgrade
- Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report)’s stock price reached a new 52-week low during trading on Monday after Scotiabank lowered their price target on the stock from $62.00 to $41.00. Scotiabank currently has a sector perform rating on the stock. Janux Therapeutics traded as low as $31.67 and last traded at $31.68, with […] - 2025-03-05 04:54:56
- New York State Common Retirement Fund Has $855,000 Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
- New York State Common Retirement Fund increased its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 84.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 15,964 shares of the company’s stock after buying an additional 7,318 shares during the period. New York State Common Retirement Fund’s holdings in Janux Therapeutics […] - 2025-03-04 06:34:50
iShares MSCI World Small Cap UCITS ETF USD (Acc) JANX holdings
| Date | Number of JANX Shares Held | Base Market Value of JANX Shares | Local Market Value of JANX Shares | Change in JANX Shares Held | Change in JANX Base Value | Current Price per JANX Share Held | Previous Price per JANX Share Held |
|---|
| 2025-10-15 (Wednesday) | 29,038 | USD 821,195 | USD 821,195 | | | | |
| 2025-10-10 (Friday) | 28,855 | USD 764,946 | USD 764,946 | | | | |
| 2025-10-08 (Wednesday) | 28,855 | USD 698,291 | USD 698,291 | | | | |
| 2025-10-07 (Tuesday) | 28,855 | USD 654,720 | USD 654,720 | 122 | USD 757 | USD 22.69 | USD 22.76 |
| 2025-10-06 (Monday) | 28,733 | USD 653,963 | USD 653,963 | 0 | USD -35,629 | USD 22.76 | USD 24 |
| 2025-10-03 (Friday) | 28,733 | USD 689,592 | USD 689,592 | 0 | USD 19,826 | USD 24 | USD 23.31 |
| 2025-10-02 (Thursday) | 28,733 | USD 669,766 | USD 669,766 | 0 | USD -11,206 | USD 23.31 | USD 23.7 |
| 2025-10-01 (Wednesday) | 28,733 | USD 680,972 | USD 680,972 | 0 | USD -21,263 | USD 23.7 | USD 24.44 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of JANX by Blackrock for IE00BF4RFH31
Show aggregate share trades of JANX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 122 | | | 22.690* | | 35.32 |
| 2025-09-08 | SELL | -244 | | | 24.810* | | 35.90 Profit of 8,759 on sale |
| 2025-08-15 | BUY | 122 | | | 25.110* | | 35.96 |
| 2025-08-07 | BUY | 360 | | | 22.580* | | 36.09 |
| 2025-07-29 | BUY | 120 | | | 24.170* | | 36.49 |
| 2025-07-14 | BUY | 244 | | | 26.180* | | 36.91 |
| 2025-06-30 | BUY | 244 | | | 23.100* | | 37.44 |
| 2025-06-25 | BUY | 366 | | | 23.240* | | 37.70 |
| 2025-06-20 | SELL | -62 | | | 23.600* | | 37.98 Profit of 2,355 on sale |
| 2025-06-12 | SELL | -496 | | | 25.560* | | 38.55 Profit of 19,121 on sale |
| 2025-06-02 | BUY | 186 | | | 25.010* | | 39.29 |
| 2025-05-28 | BUY | 124 | | | 23.700* | | 39.62 |
| 2025-05-14 | BUY | 61 | | | 22.620* | | 40.79 |
| 2025-05-13 | BUY | 122 | | | 25.330* | | 40.92 |
| 2025-05-07 | BUY | 180 | | | 25.700* | | 41.40 |
| 2025-04-28 | BUY | 60 | | | 32.230* | | 42.01 |
| 2025-04-16 | BUY | 793 | | | 28.690* | | 42.87 |
| 2025-04-14 | BUY | 122 | | | 28.950* | | 43.13 |
| 2025-04-08 | SELL | -122 | | | 23.790* | | 43.78 Profit of 5,341 on sale |
| 2025-04-04 | SELL | -124 | | | 25.770* | | 44.15 Profit of 5,474 on sale |
| 2025-03-28 | BUY | 610 | | | 29.100* | | 44.82 |
| 2025-03-12 | SELL | -122 | | | 31.810* | | 46.79 Profit of 5,709 on sale |
| 2025-03-04 | SELL | -122 | | | 29.990* | | 47.82 Profit of 5,835 on sale |
| 2025-02-26 | SELL | -244 | | | 32.600* | | 48.64 Profit of 11,868 on sale |
| 2025-02-13 | BUY | 61 | | | 37.170* | | 50.34 |
| 2025-02-12 | BUY | 244 | | | 36.780* | | 50.55 |
| 2025-01-27 | BUY | 60 | | | 43.540* | | 52.55 |
| 2025-01-23 | BUY | 60 | | | 44.590* | | 52.87 |
| 2024-12-09 | BUY | 10,630 | | | 61.650* | | 53.02 |
| 2024-12-04 | BUY | 197 | | | 66.835* | | 52.15 |
| 2024-11-19 | BUY | 234 | | | 49.010* | | 53.76 |
| 2024-11-18 | BUY | 78 | | | 48.120* | | 53.94 |
| 2024-11-12 | BUY | 152 | | | 52.840* | | 53.97 |
| 2024-11-11 | BUY | 38 | | | 53.680* | | 54.00 |
| 2024-11-11 | BUY | 38 | | | 53.680* | | 54.00 |
| 2024-11-07 | BUY | 190 | | | 54.210* | | 53.98 |
| 2024-11-07 | BUY | 190 | | | 54.210* | | 53.98 |
| 2024-10-23 | BUY | 76 | | | 51.750* | | 52.03 |
| 2024-10-23 | BUY | 76 | | | 51.750* | | 52.03 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of JANX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 172,634 | 103 | 260,402 | 66.3% |
| 2025-09-18 | 176,535 | 0 | 269,337 | 65.5% |
| 2025-09-17 | 128,859 | 60 | 187,770 | 68.6% |
| 2025-09-16 | 100,295 | 0 | 143,491 | 69.9% |
| 2025-09-15 | 108,215 | 8 | 167,209 | 64.7% |
| 2025-09-12 | 150,588 | 0 | 185,352 | 81.2% |
| 2025-09-11 | 108,500 | 0 | 160,954 | 67.4% |
| 2025-09-10 | 201,748 | 4 | 256,591 | 78.6% |
| 2025-09-09 | 113,130 | 3,850 | 173,141 | 65.3% |
| 2025-09-08 | 300,568 | 0 | 543,096 | 55.3% |
| 2025-09-05 | 62,627 | 0 | 127,575 | 49.1% |
| 2025-09-04 | 72,774 | 0 | 124,260 | 58.6% |
| 2025-09-03 | 139,012 | 7 | 192,010 | 72.4% |
| 2025-09-02 | 134,713 | 600 | 469,881 | 28.7% |
| 2025-08-29 | 96,097 | 0 | 154,984 | 62.0% |
| 2025-08-28 | 64,104 | 427 | 157,841 | 40.6% |
| 2025-08-27 | 71,132 | 0 | 106,019 | 67.1% |
| 2025-08-26 | 68,526 | 0 | 161,225 | 42.5% |
| 2025-08-25 | 108,777 | 0 | 228,045 | 47.7% |
| 2025-08-22 | 130,143 | 0 | 306,025 | 42.5% |
| 2025-08-21 | 294,442 | 197 | 430,019 | 68.5% |
| 2025-08-20 | 123,456 | 0 | 399,029 | 30.9% |
| 2025-08-19 | 154,198 | 0 | 420,303 | 36.7% |
| 2025-08-18 | 188,258 | 0 | 281,407 | 66.9% |
| 2025-08-15 | 120,890 | 500 | 169,133 | 71.5% |
| 2025-08-14 | 223,167 | 250 | 343,556 | 65.0% |
| 2025-08-13 | 429,500 | 6,636 | 623,024 | 68.9% |
| 2025-08-12 | 92,889 | 0 | 187,373 | 49.6% |
| 2025-08-11 | 111,961 | 0 | 435,053 | 25.7% |
| 2025-08-08 | 174,453 | 0 | 295,062 | 59.1% |
| 2025-08-07 | 162,162 | 0 | 434,944 | 37.3% |
| 2025-08-06 | 256,764 | 152 | 527,300 | 48.7% |
| 2025-08-05 | 300,457 | 5,008 | 552,270 | 54.4% |
| 2025-08-04 | 97,018 | 161 | 135,164 | 71.8% |
| 2025-08-01 | 132,891 | 0 | 198,035 | 67.1% |
| 2025-07-31 | 128,237 | 0 | 240,623 | 53.3% |
| 2025-07-30 | 163,198 | 5,000 | 202,607 | 80.5% |
| 2025-07-29 | 230,377 | 0 | 289,251 | 79.6% |
| 2025-07-28 | 304,963 | 0 | 376,508 | 81.0% |
| 2025-07-25 | 539,330 | 98 | 679,520 | 79.4% |
| 2025-07-24 | 190,419 | 102 | 253,752 | 75.0% |
| 2025-07-23 | 203,337 | 0 | 255,557 | 79.6% |
| 2025-07-22 | 111,092 | 171 | 168,256 | 66.0% |
| 2025-07-21 | 147,495 | 0 | 242,909 | 60.7% |
| 2025-07-18 | 218,615 | 432 | 359,526 | 60.8% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.